Literature DB >> 16172778

Acute disseminated encephalomyelitis treated with plasmapheresis.

R RamachandranNair1, M Parameswaran, A S Girija.   

Abstract

Accepted modes of therapy in acute disseminated encephalomyelitis include intravenous methyl prednisolone, intravenous immunoglobulin or a combination of both. Effectiveness of plasmapheresis has been demonstrated by previous case reports. We report two patients with steroid non-responsive acute disseminated encephalomyelitis in which plasmapheresis resulted in complete clinical and radiological recovery, though the therapy was initiated in the fifth week of illness. A total of 45-50 ml/kg body weight of plasma was removed in six equal exchanges over a period of two weeks. This report highlights that plasmapheresis could be of use even in the early second month of illness.

Entities:  

Mesh:

Year:  2005        PMID: 16172778

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  4 in total

Review 1.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

Review 2.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Treatment of acute disseminated encephalomyelitis.

Authors:  Daniela Pohl; Silvia Tenembaum
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.972

4.  Improvement of advanced postvaccinal demyelinating encephalitis due to plasmapheresis.

Authors:  Andreas Rogalewski; Jörg Kraus; Martin Hasselblatt; Christoffer Kraemer; Wolf-Rüdiger Schäbitz
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.